1989年以来荷兰早发性结直肠癌的发病率、治疗及相对生存
该研究基于荷兰癌症登记处1989至2018年数据,分析早发性结直肠癌(EO-CRC,诊断年龄<50岁)的年龄与分期别发病率、特征、治疗及相对生存趋势,并与50至59岁患者比较。结果显示EO-CRC发病率逐年上升0.7%至2.1%,III期和IV期增加而I期和II期未增加;EO-CRC接受多模式治疗略多于50至59岁患者但差异微小,相对生存随时间改善且两组间差异很小。
要点
- EO-CRC发病率近几十年每年增加0.7%至2.1%。
- III期和IV期结直肠癌在所研究各年龄组中均主要增加,I期和II期未增加。
- EO-CRC与50至59岁患者在多模式治疗和相对生存上差异微小。
核心结论
- EO-CRC与50至59岁患者之间仅发现少量流行病学和临床差异,因此针对EO-CRC在筛查和治疗指南中采取特定策略的迫切性可能被缓和。
研究设计与样本
- 研究数据来自荷兰癌症登记处,纳入1989年至2018年数据。
- 计算非标准化年龄别发病率,并使用Joinpoint回归评估趋势。
- 提供并比较EO-CRC与50至59岁患者的治疗和5年相对生存趋势。
主要发现
- EO-CRC发病率在近几十年每年增加0.7%至2.1%。
- 50至59岁人群结直肠癌发病率在2006年前每年增加0.8%至1.7%,2014年全国筛查引入后发病率大幅增加。
- III期和IV期结直肠癌在所研究年龄组中主要增加,而I期和II期未增加。
- EO-CRC患者接受多模式治疗比50至59岁患者更频繁,但差异微小。
- 相对生存随时间改善,EO-CRC与50至59岁患者之间差异很小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Previous studies showed that the incidence of early-onset colorectal cancer (EO-CRC, diagnosis <50 years) is rising in Western countries. Additionally, young patients present with more advanced disease. Integrated nationwide assessment of epidemiologically and clinically relevant trends would provide more insight into this specific group of patients with CRC. We aimed to provide an analysis of trends in age- and stage-specific incidence, characteristics, treatment and relative survival of patients with EO-CRC in the Netherlands and compare these with 50- to 59-year-old patients. METHODS: Data from 1989 to 2018 were retrieved from the Netherlands Cancer Registry. Non-standardised age-specific incidence rates were calculated, and trends were assessed using Joinpoint regression. Treatment and 5-year relative survival trends were provided and compared between EO-CRC and 50- to 59-year-old patients. RESULTS: The EO-CRC incidence annually increased with 0.7-2.1% over the last decades. CRC incidence for the 50- to 59-year-old population annually increased with 0.8-1.7% until 2006 and showed a major increase in incidence after the introduction of nationwide screening in 2014. Stage III and Stage IV CRC primarily increased across the studied age groups, while Stage I and Stage II CRC did not. Patients with EO-CRC received multimodal treatment more often than 50- to 59-year-old patients, but differences were minor. Relative survival increased over time and showed little differences between EO-CRC and 50- to 59-year-old patients. CONCLUDING STATEMENT: Only few epidemiological and clinical differences were found between EO-CRC and 50- to 59-year-old patients; hence, the urge for a specific approach of EO-CRC in screening and treatment guidelines might be tempered.
引用
- Swartjes H, Brouwer NPM, de Nes LCF, et al. Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989. Eur J Cancer. 2022. PMID: 35290914. doi:10.1016/j.ejca.2022.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。